Five-year update of an expanded phase ii study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer

Oncology

Volumn 69, Issue 5, 2005, Pages 372-383

  Abu Khalaf, Maysa M ^d   Windsor, Stephen ^a   Ebisu, Keita ^b   Salikooti, Saritha ^c   Ananthanarayanan, Gowri ^d   Chung, Gina G ^d   DiGiovanna, Michael P ^d   Haffty, Bruce G ^d   Abrams, Martin ^d   Farber, Leonard R ^d   Hsu, Arlene D ^c   Reiss, Michael ^e   Zelterman, Daniel ^b   Burtness, Barbara A ^d  

^a JERSEY SHORE UNIVERSITY MEDICAL CENTER   (United States)

^b YALE UNIVERSITY   (United States)

^c YALE CANCER CENTER   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Adjuvant therapy; Breast cancer; Cyclophosphamide; Doxorubicin; Filgrastim; Paclitaxel

Indexed keywords

CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MESNA; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTHRALGIA; ARTICLE; AXILLARY LYMPH NODE; BLEEDING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; HYPONATREMIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; TREATMENT PLANNING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; TIME FACTORS;

EID: 29144444306     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089991     Document Type: Article

References (41)

1. Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer 1989;63:181-187.
2. Valagussa P, Bonadonna G, Veronesi U: Patterns of relapse and survival following radical mastectomy. Tumori 1978;64:241-258.
3. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;113:1-15, 71-85.
4. Bonadonna G, Valagussa P, Molitierni A, Zambetti M, Brambilla C: Adjuvant cyclophosphamide, methotrexate and fluorouracil (CMF) in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-906.
5. Sledge G: Advances in monoclonal antibody therapy for breast cancer: targeting Her-2 in the adjuvant setting. Scientific Symposium, Annual Meeting of the American Society of Clinical Oncology, 2005.
6. Romond E: Advances in monoclonal antibody therapy for breast cancer: doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with positive operable breast cancer; combined analysis of NSABP-B31/ NCCTG-N9831. Scientific Symposium, Annual Meeting of the American Society of Clinical Oncology, 2005.
7. Perez E: Advances in monoclonal antibody therapy for breast cancer: further analysis of NCCTG-N9831. Scientific Symposium, Annual Meeting of the American Society of Clinical Oncology, 2005.
8. Hryniuk W, Levine MN, Levin L: Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986;4:1162-1170.
9. Wood WC, Budman DR, Korzun AH, Cooper M, Younger J, Hart R, Moore A, Ellerton J, Norton L, Ferree C: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast cancer. N Engl J Med 1994;330:1253-1259.
10. Henderson I, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S, Ingle J, Cooper M, Hayes D, Tkaczuk K, Fleming G, Holland J, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-983.
11. Fisher B, Anderson S, DeCillis A, Dimitrov N, Atkins JN, Fehrenbacher L, Henry PH, Romond EH, Lanier KS, Davila E, Kardinal CG, Laufman L, Pierce HI, Abramson N, Keller AM, Hamm JT, Wickerham DL, Begovic M, Tan-Chiu E, Tian W, Wolmark N: Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. J Clin Oncol 1999;17:3374-3388.
12. Teicher B, Cucchi C, Lee J, Flatow J, Rosowsky A, Frei E 3rd: Alkylating agents: in vitro studies of cross-resistance patterns in human tumor cell lines. Cancer Res 1986;46:4379-4383.
13. Peters WP, Rosner G, Vredenburgh J, Shpall E, Crump M, Richardson P, Schuster M, Marks L, Cirrincione C, Norton L, Henderson I, Schilsky R, Hurd D: Prospective, randomized comparison of high-dose chemotherapy with stem cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082/SWOG 9114/NCIC MA-13. J Clin Oncol 2005;23:2191-2200.
14. Tallman M, Gray R, Robert N, LeMaistre C, Osborne C, Vaughan W, Gradishar W, Pisansky T, Fetting J, Paietta E, Lazarus H: Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem cell transplantation in high-risk breast cancer. N Engl J Med 2003;349:17-26.
15. Rodenhuis S, Bontenbal M, Beex L, Wagstaff J, Richel D, Nooij M, Voest E, Hupperets P, van Tinteren H, Peterse H, TenVergert E, de Vries E: High-dose chemotherapy with hematopoietic stem cell rescue for high-risk cancer. N Engl J Med 2003;349:7-16.
16. Rodenhuis S, Bontenbal M, Beex L, Richel D, Nooij MA, Voest E, van der Wall E, Hupperets P, van Tinteren H, van de Vijver M, de Vries E: Efficacy of high dose alkylating chemotherapy in the adjuvant treatment of HER2/neu-negative primary breast cancer: update of the Dutch randomized trial (abstract 672). Proc Am Soc Clin Oncol 2005;23:465.
17. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N: Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 2000;356:1384-1391.
18. Bergh J, for the Scandanavian Breast Group Study 9401: Long-term follow-up of the randomized SBG study 9401 comparing standard FEC followed by marrow-supported high-dose therapy vs. tailored and dose-escalated FEC therapy (abstract 94). Proc Am Soc Clin Oncol 2003;22:24.
19. Roche H, Viens P, Biron P, Lotz J, Asselain B; PEGASE Group: High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control 2003;10:42-47.
20. Gianni A, Bonadonna G: Five-year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with >3 positive lymph nodes (abstract 80). Proc Am Soc Clin Oncol 2001;20:21a.
21. Crown J, Lind M, Gould A, Verril M, Twelves C, Coleman R, Perren T, Van Belle S, Cameron D, Leonard R: Failure of adjuvant peripheral progenitor-supported high-dose chemotherapy to improve the prognosis of patients with high-risk breast cancer in a randomized trial with low treatment-related mortality: the Anglo-Celtic I study (abstract 102). Ann Oncol 2002;13:2(suppl 5).
22. Combes R, Howell A, Emson M, Peckitt C, Gallagher C, Bengala C, Tres A, Welch R, Lawton P, Rubens R, Woods E, Haviland J, Vigushin D, Kanfer E, Bliss J: High-dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with 4 or more lymph nodes involved. Long-term results of an international randomized trial. Ann Oncol 2005;16:726-734.
23. Norton L, Simon R: The Norton-Simon hypothesis revisited. Cancer Treat Rep 1986;70:163-169.
24. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive lymph nodes. JAMA 1995;273:542-547.
25. Venturini M, Aitini E, Del Mastro L, Sertoli MR, Conte P, Olmeo N, Mammoliti S, Cavazzini G, Pastorino S, Bruzzi P, Rosso R: Phase II adjuvant trial comparing standard versus accelerated FEC regimen in early breast cancer patients (abstract 12). Breast Cancer Res Treat 2003;82(suppl 1):S9.
26. Hudis C, Seidman A, Baselga J, Raptis G, Lebwohl D, Gilewski T, Moynahan M, Sklarin N, Fennelly D, Crown J, Surbone A, Uhlenhopp M, Riedel E, Yao TJ, Norton L: Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. J Clin Oncol 1999;17:93-100.
27. Burtness B, Windsor S, Holston B, DiStasio S, Staugaard-Hahn C, Abrantes J, Kneuper-Hall R, Farber L, Orell J, Bober-Sorcinelli K, Haffty B, Reiss M: Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for high-risk breast cancer is feasible in the community setting. Cancer J Sci Am 1999;5:224-229.
28. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle J, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-1439.
29. Mobus V, Untch M, DuBois A: Dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide is superior to conventional dosed chemotherapy in high-risk breast cancer patients (4+ LN) (abstract 513). First results of an AGO trial. Proc Am Soc Clin Oncol 2004;23:6s.
30. Datta Y, Adams P, Drobyski W, Ethier S, Terry V, Roth M: Sensitive detection of occult breast cancer cells by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 1994:12:475-482.
31. Fields K, Elfenbein G, Trudeau W, Perkins J, Janssen W, Moscinski L: Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996;14:1868-1876.
32. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
33. Diamandidou E, Buzdar A, Smith T, Frye D, Witjaksono M, Hortobagyi G: Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 1996;14:2722-2730.
34. Crowe JP, Hubay CA, Pearson OH, Marshall JS, Rosenblatt J, Mansour EG, Hermann RE, Jones JC, Flynn WJ, McGuire WL: Estrogen receptor status as a prognostic indicator for stage I breast cancer patients. Breast Cancer Res Treat 1982;2:171.
35. Fisher B, Remond C, Fisher E, Caplan R: Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 1988;6:1076-1087.
36. Adami H, Graffman S, Lindgren A, Sallstrom J: Prognostic implication of estrogen receptor content in breast cancer. Breast Cancer Res Treat 1985;5:293-300.
37. Schmitt M, Thomssen C, Ulm K, Seiderer A, Harbeck N, Hofler H, Janicke F, Graeff H: Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-I and steroid receptor status in primary breast cancer. Br J Cancer 1997;76:306-311.
38. Costa SD, Lange S, Klinga K, Merkle E, Kaufmann M: Factors influencing the prognostic role of oestrogen and progesterone receptor levels in breast cancer: results of the analysis of 670 patients with 11 years of follow-up. Eur J Cancer 2002;38:1329-1334.
39. Overgaard M, Hansen PS, Overgaard J, Carsten R, Andersson M, Bach F, Kjaer M, Gadeberg C, Mouridsen H, Jensen M, Zedeler K: Postoperative radiation therapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med 1997;337:949-955.
40. Ragaz J, Jackson S, Le N, Plenderleith I, Spinelli J, Basco V, Wilson K, Knowling A, Coppin C, Paradis M, Coldman A, Olivotto I: Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997;337:956-962.
41. Peters W, Ross M, Vredenburgh J, Meisenberg B, Marks L, Winer E, Kurtzberg J, Bast R, Jones R, Shpall E, Wu K, Rosner G, Gilbert C, Mathias B, Coniglio D, Petros W, Henderson C, Norton L, Weiss R, Budman D, Hurd D: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993;11:1132-1143.